.Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect.The New York City-based biotech's stock cratered 30% since the data was shared earlier today, tumbling from $9.32 per share at market close Friday to $6.55 as of 10:30 a.m. ET.
- Forums
- ASX - By Stock
- NEU
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-96
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.20 |
Change
1.140(5.98%) |
Mkt cap ! $2.579B |
Open | High | Low | Value | Volume |
$19.58 | $20.52 | $19.47 | $9.631M | 477.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 181 | $20.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.24 | 245 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 181 | 20.190 |
3 | 2543 | 20.150 |
3 | 3818 | 20.120 |
2 | 2233 | 20.090 |
2 | 3602 | 20.040 |
Price($) | Vol. | No. |
---|---|---|
20.240 | 245 | 1 |
20.310 | 1116 | 2 |
20.400 | 2336 | 3 |
20.450 | 1124 | 1 |
20.500 | 3714 | 5 |
Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
Last
$20.21 |
  |
Change
1.140 ( 5.70 %) |
|||
Open | High | Low | Volume | ||
$19.56 | $20.51 | $19.53 | 123739 | ||
Last updated 15.59pm 14/05/2024 ? |
Featured News
NEU (ASX) Chart |